Rimoldi Sara Giordana, Tamoni Alessandro, Rizzo Alberto, Longobardi Concetta, Pagani Cristina, Salari Federica, Matinato Caterina, Vismara Chiara, Gagliardi Gloria, Cutrera Miriam, Gismondo Maria Rita
Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy.
Microbiology and Virology Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Pathogens. 2024 Aug 30;13(9):743. doi: 10.3390/pathogens13090743.
Bacterial infections pose significant global health challenges, often underestimated due to difficulties in accurate diagnosis, especially when culture-based diagnostics fail. This study assesses the effectiveness of 16S-based metagenomic next generation sequencing (NGS) for identifying pathogens in culture-negative clinical samples across various medical settings. Overall, 48% of samples were collected from orthopedics, 15% from neurosurgery, and 12% in cardiac surgery, among others. The detection rate of monomicrobial infections was 68.6%, and 5.7% for polymicrobial infections. In addition, NGS detected bacteria in all samples from the lungs, head and neck, and eye specimens. (11%, 12/105) was the most frequent microorganism, followed by (10.4%, 11/105), and (9.5%, 10/105). In conclusion, 16S-targeted metagenomic sequencing enhances pathogen detection capabilities, particularly in instances where traditional cultures fail. By the combination of NGS and bacterial cultures, microbiologists might provide a more accurate diagnosis, guiding more effective treatments and potentially reducing healthcare costs associated with empirical treatments.
细菌感染给全球健康带来了重大挑战,由于准确诊断存在困难,尤其是基于培养的诊断方法失败时,这些挑战常常被低估。本研究评估了基于16S的宏基因组下一代测序(NGS)在各种医疗环境中对培养阴性临床样本中病原体的识别效果。总体而言,48%的样本来自骨科,15%来自神经外科,12%来自心脏外科等。单一微生物感染的检出率为68.6%,多重微生物感染的检出率为5.7%。此外,NGS在所有来自肺部、头颈部和眼部标本的样本中均检测到了细菌。(11%,12/105)是最常见的微生物,其次是(10.4%,11/105)和(9.5%,10/105)。总之,靶向16S的宏基因组测序增强了病原体检测能力,尤其是在传统培养方法失败的情况下。通过将NGS与细菌培养相结合,微生物学家可能会提供更准确的诊断,指导更有效的治疗,并有可能降低与经验性治疗相关的医疗成本。